Figure 1.3
Adjusted incident rates of ESRD & annual percent change (page 186)
[Download]
Figure 1.3
Adjusted incident rates of ESRD & annual percent change (page 186)
[Download]
Figure 1.6
Incident counts & adjusted rates of ESRD, by race (page 186)
[Download]
Figure 1.9
Adjusted prevalent rates of ESRD & annual percent change (page 188)
[Download]
Figure 1.12
Prevalent counts & adjusted rates of ESRD, by race (page 188)
[Download]
Figure 1.15
Incident patient distribution, by first modality & payor (page 190)
[Download]
Figure 1.16
Prevalent patient distribution, by modality & payor (page 191)
[Download]
Figure 1.19
Access use at first outpatient hemodialysis, by pre-ESRD nephrology care, 2009 (page 192)
[Download]
Figure 1.20
Mean hemoglobin at initiation, by pre-ESRD ESA treatment (page 193)
[Download]
Figure 2.2
Patient distribution, by mean monthly hemoglobin (g/dl; page 198)
[Download]
Figure 2.4
Mean monthly hemoglobin after initiation, by year (page 198)
[Download]
Figure 2.15
Cumulative number of Part D medications in ESRD patients, by race/ethnicity & low income subsidy (LIS) status, 2008 (page 202)
[Download]
Figure 3.1
Change in adjusted all-cause & cause-specific hospitalization rates, by modality (page 207)
[Download]
Figure 3.4
Cause-specific rehospitalization rates 30 days post live hospital discharge, by age (page 210)
[Download]
Figure 3.7
Adj. 1st-year hosp adm rates & days (from day 90) in matched HD & PD dialysis pts
[Download]
Figure 5.1
Adjusted all-cause mortality rates, by modality & year of treatment (page 227)
[Download]
Figure 5.6
djusted all-cause mortality rates in the ESRD & general populations, by age & gender, 2009 (page 231)
[Download]
Figure 6.1
Sources of prescription drug coverage in Medicare enrollees, 2008 (page 235)
[Download]
Figure 6.15
Per person per year Medicare & out-of-pocket costs for Part D enrollees, 2008 (page 240)
[Download]
Figure 6.20
Part D non-LIS enrollees who reach each coverage phase, 2008 (page 242)
[Download]
Figure 7.1
Trends in transplantation: unadjusted rates, wait list, & total transplants, patients age 20 & older (page 249)
[Download]
Figure 7.4
Outcomes for wait-listed adult patients within three years of listing, by blood type (page 250)
[Download]
Figure 7.12
Deceased donor transplants, by age, gender, race, & primary diagnosis (page 252)
[Download]
Figure 7.14
Living donor transplants, by age, gender, race, & primary diagnosis (page 252)
[Download]
Figure 7.22
Primary diagnoses of cardiac & infectious hospitalizations in the first & second years post-transplant (page 254)
[Download]
Figure 7.32
Follow-up care & screening in the first 12 months post-transplant, by age (page 255)
[Download]
Figure 8.1
Incident & prevalent counts & adjusted rates in the pediatric ESRD population, by primary diagnosis (page 259)
[Download]
Figure 8.3
Hospital admissions for pneumonia, by modality, age, & race, 2006–2009 (page 262)
[Download]
Figure 8.10
Adjusted all-cause mortality in the first months of ESRD, by age & modality, 2001–2008 (page 265)
[Download]
Figure 10.4
Dialysis unit distribution, by affiliation & time managed (time under chain management), 2009 (page 274)
[Download]
Figure 10.5
Distribution of prevalent EPO-treated dialysis patients, by hemoglobin level & unit affiliation, 2009 (page 275)
[Download]
Figure 10.18
All-cause standardized hospitalization & mortality ratios, by unit affiliation, 2009 (page 278)
[Download]
Figure 10.19
All-cause standardized hospitalization & mortality ratios in large dialysis organizations, 2009 (page 278)
[Download]
Figure 11.6
Total Medicare ESRD expenditures, by modality (page 284)
[Download]
Figure 11.7
Total Medicare ESRD expenditures per person per year, by modality (page 284)
[Download]
Figure 11.9
Total Medicare spending for injectables (page 284)
[Download]
Figure 11.19
Total PPPY outpatient expenditures, by dialysis modality & race, 2009 (page 287)
[Download]
Figure 11.21
PPPY expenditures for ESAs, by dialysis modality & race, 2009 (page 287)
[Download]
Figure 11.22
PPPY expenditures for IV vitamin D, by dialysis modality & race, 2009 (page 287)
[Download]
Figure 11.23
PPPY expenditures for IV iron, by dialysis modality & race, 2009 (page 287)
[Download]
Figure p1
Distribution of general (fee-for-service) Medicare patients & costs for CKD, CHF, diabetes, & ESRD, 1999 & 2009
[Download]
Figure P2
Counts of new & returning dialysis patients
[Download]
Figure P3
Patient counts, by modality
[Download]
Table 2.c
Access events & complications in prevalent dialysis patients (ESRD CPM data; rate per patient year; page 201)
[Download]
Table 6.c
Top 25 drugs used by Part D-enrolled dialysis patients, by frequency & net cost, 2008 (page 244
[Download]
Table 6.d
Top 25 drugs used by Part D-enrolled transplant patients, by frequency & net cost, 2008 (page 245)
[Download]
Table 11.a
Top 25 Part D prescription drugs used in the ESRD population, by frequency & net cost, 2008 (page 288)
[Download]
Table 4.b
Cardiovascular disease & pharmacological interventions (row percent), by diagnosis and modality, 2008 (page 221)
[Download]
Table Pa 1
Summary statistics on reported ESRD therapy in the United States, by age, race, ethnicity, gender, & primary diagnosis, 2009
[Download]
Table Pa 2
Wait-list for kidney & kidney/pancreas
Table Pa 3
Medicare & non-Medicare spending*
Figure 10.1
Distribution of patients, by unit affiliation, 2009 (page 273)